
Astellas hires senior VP from rival Takeda
pharmafile | August 15, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â Astellas, Takeda, oncologyÂ
Astellas has appointed Claire Thom from fellow Japanese firm Takeda to be senior vice president of its global oncology development.
Thom will report to chief medical officer Sef Kurstjens at Astellas, and will replace Dr Wayne Klohs who recently retired.
“We ‘re thrilled that Claire is joining our experienced oncology team at Astellas,” said Kurstjens. “We believe that her unique background and varied experience, along with her approach to leadership and management will support our mission to become a global category leader in oncology. “
Thom has more than 24 years of experience in the pharma industry across a wide range of functional areas including drug development, new product planning and marketing.
Most recently she served as senior VP Portfolio Management, Drug Development Management and Strategic Business Operations at Millennium: The Takeda Oncology Company.
Related Content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer
Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination …

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer
Astellas Pharma, a pharmaceutical company creating medicines to address unmet medical needs, has announced that …

Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …




